Research Papers:
Notch1 regulates the JNK signaling pathway and increases apoptosis in hepatocellular carcinoma
Metrics: PDF 2192 views | HTML 3315 views | ?
Abstract
Chengxu Sui1*, Chengjun Zhuang2*, Deguang Sun3, Li Yang2, Liang Zhang1 and Lei Song1
1Department of Interventional Therapy, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116027, Liaoning, China
2Department of Intensive Care Unit, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116027, Liaoning, China
3Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116027, Liaoning, China
*These authors contributed equally to this work as the co-first authors
Correspondence to:
Liang Zhang, email: [email protected]
Lei Song, email: [email protected]
Keywords: Notch1, JNK, HCC
Received: October 24, 2016 Accepted: April 11, 2017 Published: April 26, 2017
ABSTRACT
Notch1-induced pathways are involved in cell growth, apoptosis, motility, and invasion in many cancers. In the present study, the expression of Notch1 and NICD1 was detected in hepatocellular carcinoma (HCC) tissues using in-vitro assays. And then, we explored cell biology and signaling pathways using Notch1 siRNA or plasmids. Here, the expression of Notch1 and NICD1 was significantly decreased in HCC tissues. In-vitro, Notch1 plasmids inhibited cell proliferation, migration and invasion, but enhanced apoptosis of HepG2 and Hep3B cells. Conversely, si-Notch1 enhanced cell proliferation, migration and invasion, but inhibited apoptosis of HepG2 and Hep3B cells. Mechanically, Notch1 decreased the expression of cyclin D1, MMP-9 and Bcl-2, but increased the expression of p-JNK, Bax and cleaved caspase 3 in HepG2 and Hep3B cells. Besides, si-JNK or JNK inhibitor SP600125 affected the activation of Notch1 signaling pathway, and prevents cell apoptosis. In conclusion, Notch1 regulates the JNK signaling pathway and increases apoptosis in HCC. Because patients with HCC have a poor prognosis, Notch1 pathway may provide a novel treatment strategy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17434